The new Aperio HALO AP system integrates multiple AI analysis applications through a single interface for streamlined workflow management.
Leica Biosystems is unveiling its Aperio HALO AP image management solution and accompanying Aperio AI Store at Pathology Visions 2025, expanding digital pathology capabilities for US laboratories through enhanced artificial intelligence (AI) integration.
The Aperio HALO AP platform, developed in partnership with Indica Labs, provides AI-powered image management with integrated digital slide review, live conferencing, and collaboration tools. The system connects to the Aperio AI Store, which offers analysis applications from multiple partners including Deep Bio, Histofy, Indica Labs, and Lunit through a unified interface.
“Building on our commitment to interoperability, we believe that providing broad access to AI analysis solutions through a single interface not only provides choice but also represents a practical solution to the growing challenge of multiple software systems and viewers,” says Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems, in a release.
Multi-Partner AI Integration Platform
The AI Store operates as a scalable analysis platform that consolidates applications from various developers into the HALO AP system. This approach addresses laboratory challenges with managing multiple software platforms and viewers by centralizing AI tools within one workflow.
Pharmaceutical companies can partner with Leica Biosystems to develop custom AI applications for the platform, potentially accelerating diagnostic development timelines, according to a release from the company. The system supports end-to-end computational pathology workflows with integration capabilities designed for algorithm scaling and deployment.
“As leaders in computational pathology, we are continually advancing the field, coupling deep expertise with sophisticated artificial intelligence,” says Steven Hashagen, CEO of Indica Labs, in a release. “This technology has the potential to not only elevate diagnostic precision and speed but also pave the way for more personalized and effective patient care.”
Pharmaceutical Partnership Expansion
The platform launch builds on Leica Biosystems’ existing pharmaceutical collaborations, including a partnership announced in May with AstraZeneca. The AI Store’s open architecture allows partners to develop and deploy algorithms while maintaining integration within the broader digital pathology workflow.
The system provides laboratories with access to AI applications that extend analysis capabilities beyond traditional manual interpretation methods. Partners can streamline development processes while delivering applications through the centralized platform interface.
Leica Biosystems operates as a cancer diagnostics company focused on anatomic and digital pathology solutions, offering products spanning the pathology workflow from sample preparation through imaging and reporting. The company functions as a subsidiary of Danaher Corporation.
ID 319647573 © HAKINMHAN | Dreamstime.com
